These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. French LE; Trent JT; Kerdel FA Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917 [TBL] [Abstract][Full Text] [Related]
8. New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited. Paquet P; Piérard GE Drug Saf; 2010 Mar; 33(3):189-212. PubMed ID: 20158284 [TBL] [Abstract][Full Text] [Related]
9. A Review of the Active Treatments for Toxic Epidermal Necrolysis. Kinoshita Y; Saeki H J Nippon Med Sch; 2017; 84(3):110-117. PubMed ID: 28724844 [TBL] [Abstract][Full Text] [Related]
10. Plasmapheresis, Intravenous Immunoglobulins, and Autologous Serum Eyedrops in the Acute Eye Complications of Toxic Epidermal Necrolysis. Pinna A; Nuvoli E; Blasetti F; Posadinu MA; Boscia F Eur J Ophthalmol; 2017 Nov; 27(6):658-663. PubMed ID: 28362052 [TBL] [Abstract][Full Text] [Related]
11. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. Gupta LK; Martin AM; Agarwal N; D'Souza P; Das S; Kumar R; Pande S; Das NK; Kumaresan M; Kumar P; Garg A; Singh S Indian J Dermatol Venereol Leprol; 2016; 82(6):603-625. PubMed ID: 27716721 [TBL] [Abstract][Full Text] [Related]
12. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome). Monteiro D; Egipto P; Barbosa J; Horta R; Amarante J; Silva P; Silva A Cutan Ocul Toxicol; 2017 Jun; 36(2):163-168. PubMed ID: 27487073 [TBL] [Abstract][Full Text] [Related]
13. Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. Houschyar KS; Tapking C; Borrelli MR; Puladi B; Ooms M; Wallner C; Duscher D; Pförringer D; Rein S; Reumuth G; Schulz T; Nietzschmann I; Maan ZN; Grieb G; Philipp-Dormston WG; Branski LK; Siemers F; Lehnhardt M; Schmitt L; Yazdi AS J Wound Care; 2021 Dec; 30(12):1012-1019. PubMed ID: 34881995 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment of toxic epidermal necrolysis using plasmapheresis: A prospective observational study. Han F; Zhang J; Guo Q; Feng Y; Gao Y; Guo L; Hou Y; An J; Wang X; Yan B; Zheng Y; Song J; Li M; Wang G J Crit Care; 2017 Dec; 42():65-68. PubMed ID: 28688239 [TBL] [Abstract][Full Text] [Related]
16. [Comment on the report "Successful treatment of Lyell's syndrome with intravenous immunoglobulins". ("Gehört-gelesen-nachgefragt") Hautarzt (1998) 49:950-951]. Mockenhaupt M; Schröder W Hautarzt; 1999 Jul; 50(7):513-4. PubMed ID: 10464687 [No Abstract] [Full Text] [Related]
17. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Stella M; Clemente A; Bollero D; Risso D; Dalmasso P Burns; 2007 Jun; 33(4):452-9. PubMed ID: 17475410 [TBL] [Abstract][Full Text] [Related]
18. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Schneider JA; Cohen PR Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852 [TBL] [Abstract][Full Text] [Related]
19. Toxic Epidermal Necrolysis Therapy with TPE and IVIG-10 Years of Experience of the Burns Treatment Center. Krajewski A; Mazurek MJ; Mlynska-Krajewska E; Piorun K; Knakiewicz M; Markowska M J Burn Care Res; 2019 Aug; 40(5):652-657. PubMed ID: 31032516 [TBL] [Abstract][Full Text] [Related]